Larvol Delta - Acumen-Publishes-Phase-1-Trial-Design-and-Clinical-Development-Plan-for-ACU193-an-AntiAmyloid-Beta-Oligomer-Antibody-for-Alzheimers-Disease

ACU193 - Acumen Pharma

https://www.globenewswire.com/news-release/2022/11/01/2545410/0/en/Acumen-Publishes-Phase-1-Trial-Design-and-Clinical-Development-Plan-for-ACU193-an-Anti-Amyloid-Beta-Oligomer-Antibody-for-Alzheimer-s-Disease.html

Nov 1, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next